Flavoxate Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Aug 24, 2022.
Flavoxate is also known as: Urispas
Flavoxate Pregnancy Warnings
Animal studies have failed to reveal evidence of impaired fertility and fetal harm. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Use is recommended only if clearly needed.
US FDA pregnancy category: B
Flavoxate Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: During long-term use, observe the breastfeeding infant for signs of decreased lactation (e.g., insatiety, poor weight gain).
See also
References for pregnancy information
- MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate" (2013):
- "Product Information. FlavoxATE Hydrochloride (flavoxATE)." PuraCap Pharmaceutical (2022):
References for breastfeeding information
- United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
- MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate" (2013):
- "Product Information. FlavoxATE Hydrochloride (flavoxATE)." PuraCap Pharmaceutical (2022):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
